PCM
RYTM icon

Penserra Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Penserra Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,514
Closed -$2.3M – 1170
2025
Q4 		$2.3M Sell
21,514
-8,922
-29% -$946K 0.03% 331
2025
Q3 		$3.07M Buy
+30,436
New +$2.83M 0.04% 312
2024
Q4 		– Sell
-25,063
Closed -$1.31M – 1184
2024
Q3 		$1.31M Buy
+25,063
New +$1.2M 0.03% 359
2021
Q4 		– Sell
-1,145
Closed -$14K – 1526
2021
Q3 		$14K Hold
1,145
– – ﹤0.01% 1303
2021
Q2 		$22K Buy
1,145
+35
+3% +$727 ﹤0.01% 1128
2021
Q1 		$23K Buy
1,110
+95
+9% +$2.75K ﹤0.01% 952
2020
Q4 		$30K Buy
1,015
+637
+169% +$16.2K ﹤0.01% 781
2020
Q3 		$8K Buy
+378
New +$8.67K ﹤0.01% 839

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Penserra Capital Management's RYTM Position: Q1 2026 in Review

Penserra Capital Management sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 21,514 shares — an estimated $2.3M sold.

Penserra Capital Management first reported a position in RYTM in Q3 2020 and held it in 8 quarters. The position peaked at $3.07M in Q3 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Penserra Capital Management reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Penserra Capital Management sold 21,514 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $2.3M.
  • Penserra Capital Management first reported a position in Rhythm Pharmaceuticals in Q3 2020 and held it in 8 quarters.
  • Penserra Capital Management's Rhythm Pharmaceuticals position peaked at $3.07M in Q3 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Penserra Capital Management's 13F filing for Q1 2026, filed 11 May 2026.